Flare Therapeutics Secures $85M in Insider-Led Series C Financing and Appoints Anna Protopapas as Chief Executive Officer

Proceeds will fund advancement of ARON degrader, FX-111, to proof of concept and preclinical development of ARON RIPTAC program- Veteran ...